152 related articles for article (PubMed ID: 37423972)
41. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Yan J; Zhou C; Guo K; Li Q; Wang Z
J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
[TBL] [Abstract][Full Text] [Related]
42. Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.
Wu Y; Wang J; Ge L; Hu Q
Oxid Med Cell Longev; 2022; 2022():5130648. PubMed ID: 35251475
[TBL] [Abstract][Full Text] [Related]
43. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma.
Tan Y; Lu L; Liang X; Chen Y
World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978
[TBL] [Abstract][Full Text] [Related]
44. Prognostic analysis of
Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
[TBL] [Abstract][Full Text] [Related]
45. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of lncRNAs related to fatty acid metabolism in lung adenocarcinoma and their correlation with tumor microenvironment based on bioinformatics analysis.
Pan YQ; Xiao Y; Long T; Liu C; Gao WH; Sun YY; Liu C; Shi YJ; Li S; Shao AZ
Front Oncol; 2022; 12():1022097. PubMed ID: 36300102
[TBL] [Abstract][Full Text] [Related]
47. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
48. Construction and validation of a glycolysis-related lncRNA signature for prognosis prediction in Stomach Adenocarcinoma.
Liao T; Lu Y; Li W; Wang K; Zhang Y; Luo Z; Ju Y; Ouyang M
Front Genet; 2022; 13():794621. PubMed ID: 36313430
[No Abstract] [Full Text] [Related]
49. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
50. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
51. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
52. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Zhu W; Ye Z; Chen L; Liang H; Cai Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
[TBL] [Abstract][Full Text] [Related]
53. Integrated analysis of a competing endogenous RNA network reveals a ferroptosis-related 6-lncRNA prognostic signature in clear cell renal cell carcinoma.
Zheng Q; Gong Z; Lin S; Ou D; Lin W; Shen P
Adv Clin Exp Med; 2024 Mar; ():. PubMed ID: 38470002
[TBL] [Abstract][Full Text] [Related]
54. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
55. A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs.
Shi GJ; Zhou Q; Zhu Q; Wang L; Jiang GQ
J Clin Lab Anal; 2022 Jun; 36(6):e24384. PubMed ID: 35441740
[TBL] [Abstract][Full Text] [Related]
56. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma.
Liu T; Sui J; Zhang Y; Zhang XM; Wu WJ; Yang S; Xu SY; Hong WW; Peng H; Yin LH; Pu YP; Liang GY
Oncol Rep; 2018 Sep; 40(3):1503-1514. PubMed ID: 30015930
[TBL] [Abstract][Full Text] [Related]
58. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
59. Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Wang P; Zeng Z; Shen X; Tian X; Ye Q
DNA Cell Biol; 2020 Apr; 39(4):615-630. PubMed ID: 32105510
[TBL] [Abstract][Full Text] [Related]
60. A four-lncRNA risk signature for prognostic prediction of osteosarcoma.
Liu H; Chen C; Liu L; Wang Z
Front Genet; 2022; 13():1081478. PubMed ID: 36685868
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
